Active-site specificity of digestive aspartic peptidases from the four species of Plasmodium that infect humans using chromogenic combinatorial peptide libraries.

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Biochemistry

• Publication date

  2005-01-22

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1021/BI047886UPMID 15697202
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Recombinant expression and enzymatic subsite characterization of plasmepsin 4 from the four Plasmodium species infecting man.

  2004cited by this paper
• Novel uncomplexed and complexed structures of plasmepsin II, an aspartic protease from Plasmodium falciparum.

  2003cited by this paper
• Computer modeling of selective regions in the active site of nitric oxide synthases: implication for the design of isoform-selective inhibitors.

  2003cited by this paper
• Plasmodium falciparum Falcilysin

  2003cited by this paper
• Expression, Purification, and Characterization of Aspartic Endopeptidases: Plasmodium Plasmepsins and “Short” Recombinant Human Pseudocathepsin

  2003cited by this paper
• Characterization of amino acid side chain losses in electron capture dissociation

  2002cited by this paper
• Side-chain radical losses from radical cations allows distinction of leucine and isoleucine residues in the isomeric peptides Gly-XXX-Arg.

  2002cited by this paper
• Automated docking to multiple target structures: Incorporation of protein mobility and structural water heterogeneity in AutoDock

  2002cited by this paper
• Active Site Contribution to Specificity of the Aspartic Proteases Plasmepsins I and II*

  2002cited by this paper
• Biological roles of proteases in parasitic protozoa.

  2002cited by this paper
• Four plasmepsins are active in the Plasmodium falciparum food vacuole, including a protease with an active-site histidine

  2002cited by this paper
• Genome sequence of the human malaria parasite Plasmodium falciparum

  2002cited by this paper
• Inhibition of Candida albicans secreted aspartic protease by a novel series of peptidomimetics, also active on the HIV-1 protease.

  2002cited by this paper
• Structures of Ser205 mutant plasmepsin II from Plasmodium falciparum at 1.8 A in complex with the inhibitors rs367 and rs370.

  2002influential reference
• Aspartic proteases of Plasmodium falciparum and other parasitic protozoa as drug targets.

  2001influential reference
• Synthesis of positional-scanning libraries of fluorogenic peptide substrates to define the extended substrate specificity of plasmin and thrombin

  2000cited by this paper
• Characterization of Native and Recombinant Falcipain-2, a Principal Trophozoite Cysteine Protease and Essential Hemoglobinase ofPlasmodium falciparum *

  2000cited by this paper
• The two sides of enzyme-substrate specificity: lessons from the aspartic proteinases.

  2000cited by this paper
• Rapid and general profiling of protease specificity by using combinatorial fluorogenic substrate libraries.

  2000cited by this paper
• FEBS Lett

  2000cited by this paper
• Identification and Characterization of Falcilysin, a Metallopeptidase Involved in Hemoglobin Catabolism within the Malaria Parasite Plasmodium falciparum*

  1999cited by this paper
• Active site specificity of plasmepsin II

  1999cited by this paper
• Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function

  1998cited by this paper
• Prime region subsite specificity characterization of human cathepsin D: The dominant role of position 128

  1998cited by this paper
• Expression and characterisation of plasmepsin I from Plasmodium falciparum.

  1997cited by this paper
• World malaria situation in 1994. Part I. Population at risk.

  1997cited by this paper
• Hemoglobin metabolism in the malaria parasite Plasmodium falciparum.

  1997cited by this paper
• Plasmodium falciparum, P. vivax, and P. malariae: a comparison of the active site properties of plasmepsins cloned and expressed from three different species of the malaria parasite.

  1997cited by this paper
• Kinetic analysis of plasmepsins I and II aspartic proteases of the Plasmodium falciparum digestive vacuole.

  1996cited by this paper
• Structure and inhibition of plasmepsin II, a hemoglobin-degrading enzyme from Plasmodium falciparum.

  1996cited by this paper
• Self-activation of Recombinant Human Lysosomal Procathepsin D at a Newly Engineered Cleavage Junction, “Short” Pseudocathepsin D*

  1996cited by this paper
• ProMod and Swiss-Model: Internet-based tools for automated comparative protein modelling.

  1996cited by this paper
• LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions.

  1995cited by this paper
• High level expression and characterisation of Plasmepsin II, an aspartic proteinase from Plasmodium falciparum

  1994cited by this paper
• Sequence, expression and modeled structure of an aspartic proteinase from the human malaria parasite Plasmodium falciparum.

  1994cited by this paper
• Molecular characterization and inhibition of a Plasmodium falciparum aspartic hemoglobinase.

  1994cited by this paper
• Analysis of proteinase specificity by studies of peptide substrates. The use of UV and fluorescence spectroscopy to quantitate rates of enzymatic cleavage.

  1994cited by this paper
• Solid-phase synthesis of peptides containing the CH2NH reduced bond surrogate.

  1994cited by this paper
• Exploration of subsite binding specificity of human cathepsin D through kinetics and rule‐based molecular modeling

  1993cited by this paper
• Human cathepsin E produced in E. coli

  1993cited by this paper
• The use of positional scanning synthetic peptide combinatorial libraries for the rapid determination of opioid receptor ligands.

  1993cited by this paper
• Rapid identification of high affinity peptide ligands using positional scanning synthetic peptide combinatorial libraries.

  1992cited by this paper
• Substrate specificity and inhibitors of aspartic proteinases.

  1992cited by this paper
• Hemoglobin degradation in the human malaria pathogen Plasmodium falciparum: a catabolic pathway initiated by a specific aspartic protease

  1991cited by this paper
• Hemoglobin degradation in the malaria parasite Plasmodium falciparum: an ordered process in a unique organelle.

  1990cited by this paper
• Subsite specificity of porcine pepsin.

  1977cited by this paper
• The specificity and mechanism of pepsin action.

  1970cited by this paper
• Kinetics of the reversible inhibition of enzyme-catalysed reactions by tight-binding inhibitors.

  1969cited by this paper

• Highlights of Medicinal Chemistry Optimization Strategies in Peptidomimetic Antimalarial Drug Discovery.

  2025cites this paper
• Plasmepsins as targets for antimalarial agents

  2020cites this paper
• Malaria parasite plasmepsins: More than just plain old degradative pepsins

  2020cites this paper
• An atypical aspartic protease modulates lateral root development in Arabidopsis thaliana.

  2019cites this paper
• Proteasas: enzimas claves en la fase esquizogónica del ciclo de vida de Plasmodium falciparum / Proteases: key enzymes in the schizogonic phase of Plasmodium falciparum life cycle

  2019cites this paper
• Proteolysis assessment in isolated Plasmodium falciparum living cells at the asexual blood stages

  2018cites this paper
• Targeting the active sites of malarial proteases for antimalarial drug discovery: approaches, progress and challenges.

  2017cites this paper
• Plasmepsin: Function, Characterization and Targeted Antimalarial Drug Development

  2017cites this paper
• Functional and structural characterization of synthetic cardosin B-derived rennet

  2017influential citation
• Enzymatic properties, evidence for in vivo expression, and intracellular localization of shewasin D, the pepsin homolog from Shewanella denitrificans

  2016cites this paper
• New paradigm of an old target: an update on structural biology and current progress in drug design towards plasmepsin II.

  2015cites this paper
• Enzymatic Characterization of Recombinant Food Vacuole Plasmepsin 4 from the Rodent Malaria Parasite Plasmodium berghei

  2015cites this paper
• Análisis in silico de la naturaleza de las interacciones que determinan la especificidad y la selectividad de la plasmepsina II del Plasmodium falciparum por sus sustratos e inhibidores: implicaciones para el diseño de inhibidores más selectivos

  2014cites this paper
• Preliminary Studies on the Expression and Purification of Functionally Active Recombinant Plasmepsin 9 from Plasmodium falciparum

  2013cites this paper
• Development of Plasmodium falciparum protease inhibitors in the past decade (2002-2012).

  2013cites this paper
• An Aspartic Protease of the Scabies Mite Sarcoptes scabiei Is Involved in the Digestion of Host Skin and Blood Macromolecules

  2013cites this paper
• Chapter 15 – Pregnancy-Associated Glycoproteins

  2013cites this paper
• Drugs for Parasitic Infections: Advances in the Discovery of New Antimalarials

  2013cites this paper
• Non-combinatorial library screening reveals subsite cooperativity and identifies new high-efficiency substrates for kallikrein-related peptidase 14

  2012cites this paper
• The Plasmepsin Family as Antimalarial Drug Targets

  2011cites this paper
• Computational Perspectives into Plasmepsins Structure—Function Relationship: Implications to Inhibitors Design

  2011cites this paper
• Sequence homology and structural analysis of plasmepsin 4 isolated from Indian Plasmodium vivax isolates.

  2011cites this paper
• Plasmodium vivax: collaborative roles for plasmepsin 4 and vivapains in hemoglobin hydrolysis.

  2011cites this paper
• Plasmepsins Inhibitors as Potential Drugs against Malaria: Starving the Parasite

  2011cites this paper
• Introduction to the Aspartic Proteinase Family

  2011cites this paper
• Characterisation of aspartic protease activity from the scabies mite Sarcoptes scabiei

  2011influential citation
• An examination of the proteolytic activity for bovine pregnancy-associated glycoproteins 2 and 12

  2010cites this paper
• alpha-Substituted norstatines as the transition-state mimic in inhibitors of multiple digestive vacuole malaria aspartic proteases.

  2009cites this paper
• Plasmodium falciparum: new molecular targets with potential for antimalarial drug development

  2009cites this paper
• Subsite cooperativity in protease specificity

  2009cites this paper
• Recombinant plasmepsin 1 from the human malaria parasite plasmodium falciparum: enzymatic characterization, active site inhibitor design, and structural analysis.

  2009cites this paper
• Evidence for Catalytic Roles for Plasmodium falciparum Aminopeptidase P in the Food Vacuole and Cytosol*

  2009cites this paper
• Characterization of novel plasmepsins from the malaria parasite Plasmodium falcipaurm

  2009cites this paper
• An analysis of aspartic peptidases expressed by trophoblasts and placenta of even-toed ungulates

  2008cites this paper
• Predicting functional residues in Plasmodium falciparum plasmepsins by combining sequence and structural analysis with molecular dynamics simulations

  2008cites this paper
• Characterization of the peptidase activity of recombinant porcine pregnancy-associated glycoprotein-2.

  2008cites this paper
• Analysis of binding interactions of pepsin inhibitor-3 to mammalian and malarial aspartic proteases.

  2007influential citation
• Advances in the Discovery of New Antimalarials

  2007cites this paper
• Selection of new chromogenic substrates of serine proteinases using combinatorial chemistry methods.

  2007cites this paper
• Inhibitor binding to the plasmepsin IV aspartic protease from Plasmodium falciparum.

  2006cites this paper
• Plasmepsins as potential targets for new antimalarial therapy

  2006influential citation
• Activation, Proteolytic Processing, and Peptide Specificity of Recombinant Cardosin A*

  2005cites this paper
• Pregnancy-Associated Glycoproteins

  2004cites this paper